



CORRECTION

Correction to: Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA

Kwame Owusu-Edusei · Arijita Deb · Kelly D. Johnson

Published online: March 6, 2022
© The Author(s) 2022

Correction to: Infect Dis Ther
<https://doi.org/10.1007/s40121-022-00588-x>

In the original publication of the article, Fig. 1 was erroneously published. The correct version of the Fig. 1 is corrected here.




Fig. 1 Markov model structure. IPD invasive pneumococcal disease, NBPP non-bacteremic pneumococcal pneumonia. Background mortality is applied to all health states in the model

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40121-022-00588-x>.

K. Owusu-Edusei (✉) · A. Deb · K. D. Johnson
Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA
e-mail: kwame.owusu-edusei@merck.com